Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework

Reka E. Pataky,Stuart Peacock,Stirling Bryan,Mohsen Sadatsafavi,Dean A. Regier

DOI: https://doi.org/10.1007/s40258-024-00926-9

2024-11-10

Applied Health Economics and Health Policy

Abstract:Mutations in KRAS and NRAS are predictive of poor response to cetuximab and panitumumab, two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies used in metastatic colorectal cancer (mCRC). Our objective was to explore the value of using KRAS and NRAS mutation status to inform third-line anti-EGFR therapy for mCRC using the value of heterogeneity (VOH) framework.

health care sciences & services,health policy & services,economics